

1 **Title page**

2

3 **Original Article**

4

5 **Authors:** Victor A. Andrade-Souza<sup>1</sup>, Thaysa Ghiarone<sup>1</sup>, Andre Sansonio<sup>1</sup>, Kleiton  
6 Augusto Santos Silva<sup>1,2</sup>, Fabiano Tomazini<sup>1</sup>, Lucyana Arcoverde<sup>1</sup>, Jackson Fyfe<sup>3</sup>,  
7 Enrico Perri<sup>4</sup>, Nicholas Saner<sup>4</sup>, Jujiao Kuang<sup>4</sup>, Romulo Bertuzzi<sup>5</sup>, Carol Gois Leandro<sup>1</sup>,  
8 David J. Bishop<sup>4,6,\*</sup> and Adriano E. Lima-Silva<sup>1,7</sup>

9

10 **Title of Article:** Exercise twice-a-day potentiates skeletal muscle signalling responses  
11 associated with mitochondrial biogenesis in humans, which are independent of lowered  
12 muscle glycogen content

13

14 **Author's Institutions:**

15 <sup>1</sup>Department of Physical Education and Sports Science, Academic Center of Vitoria,  
16 Federal University of Pernambuco, Vitoria de Santo Antao, Pernambuco, Brazil

17 <sup>2</sup>Department of Medicine, University of Missouri School of Medicine, Columbia,  
18 Missouri, USA

19 <sup>3</sup>School of Exercise and Nutrition Sciences, Faculty of Health, Deakin University,  
20 Burwood, Victoria, Australia

21 <sup>4</sup>Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia

22 <sup>5</sup>Endurance Performance Research Group, School of Physical Education and Sport,  
23 University of São Paulo, Sao Paulo, Brazil

24 <sup>6</sup>School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western  
25 Australia, Australia

26 <sup>7</sup>Human Performance Research Group, Academic Department of Physical Education,  
27 Technological Federal University of Parana, Curitiba, Parana, Brazil

28

29 **\*Correspondence and requests for materials should be addressed to:**

30 David John Bishop

31 Institute for Sport and Health, Victoria University. PO Box 14428, Melbourne VIC  
32 8001, Australia. Phone: +61 3 9919 9471. E-mail address: David.Bishop@vu.edu.au

33

34 **Conflict of Interest:** The authors declare no conflict of interest.

35 **Abstract**

36 Endurance exercise begun with reduced muscle glycogen stores seems to potentiate  
37 skeletal muscle protein abundance and gene expression. However, it is unknown  
38 whether this greater signalling responses is due to low muscle glycogen *per se* or to  
39 performing two exercise sessions in close proximity - as a first exercise session is  
40 necessary to reduce the muscle glycogen stores. In the present study, we manipulated  
41 the recovery duration between a first muscle glycogen-depleting exercise and a second  
42 exercise session, such that the second exercise session started with reduced muscle  
43 glycogen in both approaches but was performed either two or 15 h after the first  
44 exercise session (so-called “twice-a-day” and “once-daily” approaches, respectively).  
45 We found that exercise twice-a-day increased the nuclear abundance of transcription  
46 factor EB (TFEB) and nuclear factor of activated T cells (NFAT) and potentiated the  
47 transcription of peroxisome proliferator-activated receptor- $\gamma$  coactivator 1 alpha (PGC-  
48  $1\alpha$ ), peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) and peroxisome  
49 proliferator-activated receptor beta/delta (PPAR $\beta/\delta$ ) genes, in comparison with the  
50 once-daily exercise. These results suggest that the elevated molecular signalling  
51 reported with previous “train-low” approaches can be attributed to performing two  
52 exercise sessions in close proximity rather than the reduced muscle glycogen content  
53 *per se*. The twice-a-day approach might be an effective strategy to induce adaptations  
54 related to mitochondrial biogenesis and fat oxidation.

55

56           Endurance exercise is a powerful stimulus affecting cytoplasmic and nuclear  
57 proteins, and genes encoding mitochondrial proteins, with a subsequent increase in  
58 mitochondrial biogenesis (i.e., the generation of new mitochondrial components leading  
59 to increased mitochondrial content and respiratory function)<sup>1-8</sup>. While these responses  
60 are affected by the nature of the exercise (e.g., the exercise intensity<sup>2, 9</sup>), there is  
61 evidence substrate availability is also a potent modulator of this response<sup>10-13</sup>. It has  
62 been hypothesised that initiating endurance exercise with low muscle glycogen stores  
63 (the so-called “train-low” approach) results in a greater increase in the transcription of  
64 genes associated with mitochondrial biogenesis<sup>14-17</sup>. If performing exercise with reduced  
65 muscle glycogen modifies the transcriptional response, it could be hypothesised that  
66 there will also be concomitant changes in the content of nuclear proteins that regulate  
67 gene transcription. However, while this information could provide important  
68 mechanistic insights, the response of nuclear proteins to the train-low approach in  
69 humans has not been assessed.

70

71           Although the train-low strategy seems to be a potent approach to potentiate  
72 skeletal muscle signalling responses related to mitochondrial biogenesis<sup>14, 18-20</sup>, there are  
73 also contrasting findings showing no effects<sup>17, 21-24</sup> and a consensus is yet to be reached.  
74 Furthermore, much of the evidence supporting the train-low approach is based on  
75 performing a first exercise session to reduce muscle glycogen stores, which is followed  
76 by a second exercise session one to three hours later – the so-called “twice-a-day”  
77 approach<sup>18-22, 24, 25</sup>. Although the second exercise session will start with reduced muscle  
78 glycogen stores, it is challenging to determine if any changes are due to performing the  
79 second exercise session with low muscle glycogen or performing the second exercise  
80 session soon after the first. It is well known that the transcriptional response of many

81 genes peak 3 to 6 hours post exercise and return to basal levels within 8 to 12 h<sup>5, 13, 26-29</sup>.  
82 Thus, it is possible that reported increases in gene expression with the twice-a-day  
83 approach can be attributed to performing the second exercise session close to the first,  
84 when there is an already increased expression of genes associated with mitochondrial  
85 biogenesis.

86

87 Therefore, the aim of this study was to investigate whether previous reports of  
88 greater exercise-induced signalling with the train-low approach can be attributed to low  
89 muscle glycogen *per se* or to the cumulative effect of performing two exercise sessions  
90 in close proximity. In the present study, we manipulated the recovery duration between  
91 a first muscle glycogen-depleting exercise and a second exercise session (i.e., a “once-  
92 daily” vs. a “twice-a-day” approaches). In the once-daily condition, muscle glycogen  
93 content was reduced via evening exercise (prolonged exercise) followed by a  
94 carbohydrate (CHO)-restricted period, and a second exercise (i.e., high-intensity  
95 interval exercise; HIIE) on the next day (i.e., 15 h between exercises sessions). In the  
96 twice-a-day condition, the same exercises were used but with a short recovery period  
97 between exercise sessions (i.e., 2 h between exercise sessions). A HIIE session  
98 undertaken without a prior muscle glycogen-depleting exercise served as a control.

99

100 We demonstrated for the first time that performing two exercise sessions in close  
101 succession increases the abundance of transcription factor EB (TFEB) and nuclear  
102 factor of activated T cells (NFAT) proteins in the nucleus. We also showed that exercise  
103 twice-a-day potentiates the transcription of peroxisome proliferator-activated receptor-  
104 □ coactivator 1 alpha (PGC-1 $\alpha$ ), peroxisome proliferator-activated receptor alpha  
105 (PPAR $\alpha$ ) and peroxisome proliferator-activated receptor beta/delta (PPAR $\beta/\delta$ ) - genes

106 that have been associated with mitochondrial biogenesis and fat metabolism. These data  
107 suggest that the elevated molecular signalling when starting an exercise session with  
108 reduced muscle glycogen content can be attributed to performing two exercise sessions  
109 in close succession rather than the reduced muscle glycogen content *per se*. Further  
110 research is required to investigate if the twice-a-day approach is a more effective  
111 training strategy to induce adaptations related to mitochondrial biogenesis and fat  
112 oxidation.

113

## 114 **Results**

115 **Muscle glycogen concentration.** To examine whether the second exercise session  
116 started with similarly low levels of muscle glycogen in the twice-a-day and once-daily  
117 approaches, we analysed the muscle glycogen content via enzymatic analysis with  
118 fluorometric assay detection<sup>30</sup>. Prior to the HIIE, muscle glycogen concentration was  
119 similarly lower in both the twice-a-day and once-daily conditions, compared to the  
120 control condition (Fig. 1). Muscle glycogen concentration was below 300 mmol·kg<sup>-1</sup>·dry  
121 mass for both the twice-a-day and once-daily conditions. This value has been suggested  
122 as an “upper limit threshold”, above which muscle glycogen will not modulate the  
123 activation of acute and chronic skeletal muscle adaptations with the “train-low”  
124 approach<sup>31</sup>. Muscle glycogen concentration decreased similarly after the HIIE in all  
125 three conditions ( $P < 0.05$ ) and remained lower 3 h post HIIE in both the twice-a-day  
126 and once-daily conditions, compared to the control condition. Post HIIE muscle  
127 glycogen concentration remained above 100 mmol·kg<sup>-1</sup>·dry mass. This value has been  
128 hypothesised as a “lower limit threshold”, below which muscle glycogen will not  
129 continue modulating genes related to mitochondrial biogenesis<sup>31</sup>. These findings  
130 suggest that the HIIE in both twice-a-day and once-daily approaches were performed

131 with muscle glycogen levels compatible with the “train-low” approach. In addition, the  
132 HIIIE was initiated with similarly low levels of muscle glycogen in both the once-daily  
133 and twice-a-day conditions. Therefore, any differences in cytosolic and nuclear protein  
134 abundance and gene expression responses between these two exercising approaches can  
135 be attributed to the different recovery duration between the two exercise, rather than the  
136 starting muscle glycogen concentration.

137

138 (PLEASE INSERT FIGURE 1 HERE)

139

140 **Cytosolic proteins relative abundance pre and post HIIIE.** Given that the muscle  
141 glycogen concentration was similar between both the twice-a-day and once-daily  
142 conditions, we next investigated whether the two exercising approaches had a similar  
143 effect on exercise-induced changes in cytosolic protein relative abundance.  
144 Representative blots are presented in Fig. 2a. Cytosolic p53 protein relative abundance  
145 increased immediately post HIIIE in all three conditions (Fig. 2c), with no differences  
146 between conditions. Cytosolic PGC-1 $\alpha$ , phosphorylated p53 (p-p53<sup>Ser15</sup>), PHF20 protein  
147 (PHF20), TFEB, p38 mitogen-activated protein kinase (p38MAPK), phosphorylated 5'  
148 adenosine monophosphate-activated protein kinase (p-AMPK<sup>Thr172</sup>) and NFAT relative  
149 abundance were unaffected by the exercise approach or time (Fig. 2b, 2d-i).  
150 Collectively, these data reveal that neither “train-low” approach influenced exercise-  
151 induced changes in the cytosolic proteins assessed in the present study.

152

153 (PLEASE INSERT FIGURE 2 HERE)

154

155 **Nuclear protein relative abundance pre and post HIIE.** Given that cytosolic proteins  
156 can rapidly translocate to the nucleus, and the exercise-induced changes are often not  
157 observed in the cytoplasm<sup>4, 32</sup>, we next investigated whether either “train-low” approach  
158 altered exercise-induced changes in nuclear protein relative abundance. Representative  
159 blots are presented in Fig. 3a. Nuclear PGC-1 $\alpha$ , p53, and p-p53<sup>Ser15</sup> relative abundance  
160 increased post HIIE (Fig. 3b-d), with no clear differences between the three conditions.  
161 The relative abundance of nuclear PHF20, p38MAPK, and p-AMPK<sup>Thr172</sup> was  
162 unaffected by either “train-low” approach or time (Fig. 3e-g). However, nuclear TFEB  
163 relative abundance was greater in the twice-a-day compared to the once-daily condition  
164 both pre and post HIIE (Fig. 3h). Moreover, nuclear NFAT relative abundance was also  
165 greater in the twice-a-day compared to both the once-daily and control condition post  
166 HIIE (Fig. 3i). Because TFEB and NFAT can act as transcription factors for several  
167 genes involved in mitochondrial biogenesis<sup>32-35</sup>, potential downstream pathways were  
168 further explored.

169

170 (PLEASE INSERT FIGURE 3 HERE)

171

172 **Mitochondrial-related gene expression pre, post, and 3 h post HIIE.** Since we  
173 observed a greater relative abundance of nuclear TFEB and NFAT with the twice-a-day  
174 approach, we further compared the expression of several related genes. Pre HIIE, total  
175 PGC-1 $\alpha$  mRNA content was ~9-fold higher in the twice-a-day compared to both the  
176 once-daily and control conditions (Fig. 4a). Three hours post HIIE, total PGC-1 $\alpha$   
177 mRNA content increased in all three conditions compared with their respective pre-  
178 values; however, total PGC-1 $\alpha$  mRNA content remained ~10-fold higher in the twice-a-  
179 day compared to both control and once-daily conditions. Similarly, PGC-1 $\alpha$  isoform 4

180 mRNA content was ~24-fold higher at pre HIIE in the twice-a-day compared to both the  
181 once-daily and control conditions (Fig. 4c). At 3 h post HIIE, the PGC-1 $\alpha$  isoform 4  
182 mRNA content increased in all three conditions compared with their respective pre-  
183 values; however, the PGC-1 $\alpha$  isoform 4 mRNA content remained ~10-fold higher in the  
184 twice-a-day compared to the control and once-daily conditions. Additionally, PGC-1 $\alpha$   
185 isoform 1 mRNA content was higher in the twice-a-day compared to the once-daily  
186 when all time points were considered (two-way ANOVA, main effect of condition,  $p <$   
187 0.05, Fig. 4b). There was, however, no effect of condition for p53, TFEB,  
188 chromodomain-helicase-DNA-binding protein 4 (CHCHD4), p21, mitochondrial  
189 transcription factor A (Tfam), NADH dehydrogenase subunit  $\beta$  (NDUF $\beta$ ; mitochondrial  
190 complex I), succinate dehydrogenase subunit  $\beta$  (SDH $\beta$ ; mitochondrial complex II),  
191 cytochrome c (mitochondrial complex III), and cytochrome c oxidase subunit IV (COX  
192 IV; mitochondrial complex IV) mRNA content (Fig. 4d-l). The mRNA content of  
193 representative subunits of mitochondrial complexes II, III, and IV increased 3 h post  
194 HIIE to a similar extent for all three conditions. Thus, the transcription of PGC-1 $\alpha$  (and  
195 its isoforms) are potentiated by performing two exercise sessions in close succession,  
196 although exercise-induced increases in mitochondrial complex genes were not affected  
197 by the different “train-low” approaches.

198

199 (PLEASE INSERT FIGURE 4 HERE)

200

201 **Fat transport and lipolysis related genes pre, post, and 3 h post HIIE.** Since the  
202 twice-a-day approach increased the nuclear abundance of TFEB, which could affect  
203 genes related to fat metabolism<sup>32, 35</sup>, we also assessed changes in a selection of genes  
204 associated with fat transport and lipolysis. The content of carnitine palmitoyltransferase



205 I subunit A (CPT1A) mRNA was higher in both the twice-a-day and once-daily  
206 conditions compared with the control condition at 3 h post HIIE; however, there was no  
207 difference between the two “train-low” approaches (Fig. 5a). There was an increase in  
208 mitochondrial uncoupling protein 3 (UCP3) mRNA content 3 h post exercise in all three  
209 conditions. The UCP3 mRNA content was, however, significantly higher only in the  
210 twice-a-day compared to the control condition at 3 h post HIIE (Fig. 5b). Pre HIIE, the  
211 PPAR $\alpha$  mRNA content was ~11-fold higher in the twice-a-day compared to both the  
212 once-daily and control conditions (Fig. 5c). Three hours post HIIE, the PPAR $\alpha$  mRNA  
213 content increased ~7- and 9-fold in the once-daily and control conditions, respectively,  
214 compared with their respective pre-values; however, the PPAR $\alpha$  mRNA content  
215 remained ~16-fold higher in the twice-a-day compared to the once-daily and control  
216 conditions. The PPAR $\beta/\delta$  mRNA content was higher in the twice-a-day than in the  
217 control condition post HIIE, and higher than both the once-daily and control conditions  
218 at 3 h post HIIE (Fig. 5d). The PPAR $\beta/\delta$  mRNA content was higher at 3 h post HIIE  
219 compared to pre- and post HIIE only for the twice-a-day approach. The citrate synthase  
220 (CS) mRNA content was higher 3 h post HIIE compared to post HIIE for all three  
221 conditions. However, the peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ),  
222  $\beta$ -hydroxyacyl-CoA dehydrogenase ( $\beta$ -HAD), and fatty acid translocase cluster of  
223 differentiation 36 (CD-36) mRNA content were unaffected by “train-low” approach or  
224 time (Fig. 5e-h). Thus, performing two exercise sessions in close succession potentiates  
225 the transcription of PPAR $\alpha$ , PPAR $\beta/\delta$  and UCP3, while exercise-induced changes in  
226 CPT1A mRNA content seemed to be influenced by low muscle glycogen stores *per se*  
227 as it was similarly increased by HIIE in both the twice-a-day and the once-daily  
228 conditions.  
229

230 (PLEASE INSERT FIGURE 5 HERE)

231

232 **Glycolysis related genes pre, post and 3 h post HIIE.** As the train-low strategy has  
233 been reported to affect CHO pathways<sup>4</sup>, we also assessed exercise-induced changes in  
234 genes associated with CHO metabolism. The mRNA content of phosphofructokinase  
235 (PFK) and glucose transporter 4 (GLUT4) was unaffected by exercising approach or  
236 time. While pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) mRNA content  
237 increased 3 h post HIIE, there was no difference for the three different exercising  
238 approaches (Fig. 6a-c). These findings indicate that exercise-induced changes in genes  
239 related to CHO metabolism were not influenced by muscle glycogen stores or the  
240 proximity of the two exercise sessions in the present study.

241

242 (PLEASE INSERT FIGURE 6 HERE)

243

244 **Physiological responses pre, post, and 3 h post HIIE.** The twice-a-day approach was  
245 associated with a higher heart rate, ventilation, and oxygen uptake, and a lower plasma  
246 glucose concentration during HIIE than both the once-daily and the control condition  
247 (Fig. 7a-c and Table 1). Plasma glucose was also lower during HIIE in the once-daily  
248 compared to the control condition (Table 1). In addition, the respiratory exchange ratio  
249 was lower and the serum free fatty acid concentration higher than the control only for  
250 the twice-a-day approach (Fig. 7d and Table 1). Serum glycerol was higher and plasma  
251 lactate lower post HIIE in both the twice-a-day and once-daily conditions compared  
252 with the control condition (Table 1). Plasma epinephrine and norepinephrine  
253 concentration was not influenced by the exercising approach undertaken. Together,

254 these findings suggest a higher systemic physiological stress and a higher fat oxidation  
255 rate with the twice-a-day compared with the once-daily and control conditions.

256

257 (PLEASE INSERT FIGURE 7 HERE)

258 (PLEASE INSERT TABLE 1 HERE)

259

## 260 **Discussion**

261 There is continued debate about whether beginning exercise with low muscle  
262 glycogen stores potentiates the exercise-induced increase in genes associated with  
263 mitochondrial biogenesis and metabolism<sup>10, 11, 31, 36-39</sup>. Some of this controversy may  
264 relate to the observation that much of the evidence supporting the train-low approach is  
265 based on performing the experimental exercise session a few hours after a glycogen-  
266 lowering exercise session<sup>18-22, 25</sup>. Thus, it is difficult to determine if any observed effects  
267 are due to performing the second exercise session with low muscle glycogen stores  
268 and/or performing the second exercise session close to the first. We aimed to resolve  
269 this controversy by performing the same exercise session with similar starting muscle  
270 glycogen stores, but either 2 or 15 hours following the previous glycogen-lowering  
271 exercise session. In contrast to previous suggestions, our results indicate that the greater  
272 exercise-induced nuclear protein abundance (TFEB and NFAT) and transcription of  
273 genes involved in mitochondrial biogenesis (PGC-1 $\alpha$ , PPAR $\alpha$ , PPAR $\beta/\delta$ ) with the so-  
274 called “train-low” approach can be attributed to performing two exercise sessions in  
275 close proximity and is not due to low muscle glycogen *per se*.

276

277 Despite the different recovery periods between exercise sessions for the two  
278 train-low approaches, muscle glycogen prior to the HIIE was reduced to a similar extent

279 in both the twice-a-day and once-daily condition compared with the control condition  
280 (45 and 42% from control, respectively, Fig. 1). This level of muscle glycogen  
281 concentration is consistent with previous studies that have utilised either the twice-a-  
282 day<sup>19, 20</sup> or once-daily<sup>17</sup> approach. The similar low muscle glycogen levels when  
283 commencing the HIIE in both “train-low” conditions allowed us to investigate whether  
284 any differences for exercise-induced gene or protein expression could be attributed to  
285 performing HIIE with reduced muscle glycogen stores or to performing HIIE close to a  
286 previous exercise session.

287

288 The train-low approach has been associated with a greater exercise-induced  
289 activation of genes associated with mitochondrial biogenesis and fat metabolism<sup>14, 17, 19,</sup>  
290 <sup>20</sup>. However, to our knowledge, no study has investigated the effect of different train-  
291 low strategies on exercise-induced changes in the nuclear abundance of proteins  
292 associated with the transcriptional activation of mitochondrial biogenesis and fat  
293 metabolism. Consistent with previous research<sup>14, 17, 40, 41</sup>, immediately post HIIE there  
294 was greater PGC-1 $\alpha$ , p-p53, and p53 relative protein abundance in the nucleus (Fig. 3b-  
295 d). However, there were no significant differences between either of the train-low  
296 approaches and the control condition. Similarly, neither train-low approach affected the  
297 nuclear abundance of p-AMPK or p-p38 MAPK (Fig. 3f,g). This indicates that lowering  
298 muscle glycogen levels did not affect the nuclear abundance of these proteins, at rest or  
299 following HIIE. We subsequently investigated the nuclear abundance of other proteins  
300 that may contribute to previous reports of greater exercise-induced increases in gene  
301 expression with different train-low approaches.

302

303 Despite evidence from animal studies<sup>32, 34, 35, 42, 43</sup>, to our knowledge this is the  
304 first study to report an exercise-induced increase in the nuclear protein abundance of  
305 TFEB and NFAT in human skeletal muscle. Another novel finding of the present study  
306 was that the nuclear abundance of both NFAT and TFEB was significantly greater with  
307 the twice-a-day approach compared to both the once-daily and control conditions (Fig.  
308 3h,i). Furthermore, the exercise-induced increase in the nuclear abundance of NFAT  
309 was only significant in the twice-a-day condition. As activated calcineurin  
310 dephosphorylates both NFAT<sup>34, 42</sup> and TFEB<sup>32, 35, 43</sup>, leading to their translocation to the  
311 nucleus<sup>32-35, 42, 43</sup>, this suggests there might be greater calcineurin activation when a  
312 second exercise session is performed soon after a prior exercise session. Unfortunately,  
313 we did not have sufficient muscle sample to test this hypothesis and further research is  
314 required. Nonetheless, as activated calcineurin has been implicated in the expression of  
315 many genes<sup>33</sup>, we also investigated the effect of our two different train-low approaches  
316 on the expression of selected metabolic and mitochondrial genes.

317

318 In the twice-a-day condition, we observed significantly greater exercise-induced  
319 increases in genes that have been reported to be regulated by calcineurin<sup>33</sup> (e.g., PGC-  
320 1 $\alpha$ , PPAR $\alpha$ , PPAR $\beta/\delta$ ; Fig. 4 and 5). This effect was not observed in the once-daily  
321 condition; this suggests that the greater exercise-induced increase in these genes can be  
322 attributed to performing HIIE soon after the prior exercise session, rather than  
323 beginning HIIE with lowered muscle glycogen levels. There were not greater exercise-  
324 induced increases in other investigated genes that have previously been reported to be  
325 activated by calcineurin (e.g., PPAR $\gamma$ , CS, CD-36, and GLUT4; Fig. 4, 5 and 6). In the  
326 case of PPAR $\gamma$ , others have also reported no effect of exercise on PPAR $\gamma$  gene  
327 expression<sup>44</sup> and this probably explains why we observed no effect of any condition on

328 the exercise-induced expression of this gene. Regarding CS, CD-36, and GLUT4, others  
329 have reported that the expression of these genes is not increased until more than 6 h post  
330 exercise<sup>44-46</sup> and it may be that our biopsy timing (3 h post HIIE) did not allow us to  
331 detect significant differences in the expression of these genes with exercise or between  
332 conditions.

333

334 Consistent with previous research, we observed a robust increase in PGC-1 $\alpha$   
335 mRNA content following HIIE<sup>2, 14, 17</sup>. However, although it has been suggested that  
336 commencing exercise with low muscle glycogen can amplify the increase in genes  
337 associated with mitochondrial biogenesis<sup>14, 16, 17</sup>, there were no differences in post-HIIE  
338 PGC-1 $\alpha$  mRNA content between the once-daily and control conditions. However, in the  
339 present study, the total PGC-1 $\alpha$  and PGC-1 $\alpha 4$  mRNA content were higher (~10-fold) in  
340 the twice-a-day approach, compared to the once-daily and control 3 h post HIIE (Fig.  
341 4a-c). Additionally, PPAR $\alpha$  and PPAR $\beta/\delta$  mRNA content was also higher in the twice-  
342 a-day compared to the once-daily and control 3 h post HIIE (~16- to 2-fold,  
343 respectively; Fig. 5c-d). Together, PGC-1 $\alpha$ , PPAR $\alpha$  and PPAR $\beta/\delta$  regulate the  
344 expression of genes related to fat metabolism<sup>33</sup>. Recent findings have also indicated that  
345 PPAR $\beta/\delta$  is a potent protector of PGC-1 $\alpha$  against degradation, and can regulate  
346 mitochondrial respiratory chain proteins, which suggests PPAR $\beta/\delta$  also plays an  
347 essential role in exercise-induced mitochondrial biogenesis<sup>47</sup>. Therefore, our findings  
348 indicate the twice-a-day approach may be a more effective strategy to increase both  
349 mitochondrial biogenesis and fat metabolism. This is consistent with studies that have  
350 reported greater increases in CS activity<sup>20, 25</sup> and whole-body fat oxidation during sub-  
351 maximal exercise<sup>18, 20</sup> when training twice-a-day compared to once-daily training.

352

353 In the twice-a-day condition we also observed a greater circulating FFA at pre,  
354 post, and 3-h post HIIE (Table 1), and a lower RER throughout the HIIE (Fig. 7), which  
355 is indicative of greater fat oxidation. The increase in circulating FFA might activate  
356 calcineurin<sup>52</sup>, resulting in the regulation of skeletal muscle metabolism via coordinated  
357 changes in gene expression<sup>33</sup>. Activated calcineurin will lead to a translocation of both  
358 NFAT and TFEB to the nucleus<sup>32-35, 42, 43</sup>. Translocated NFAT will promote the  
359 expression of PPAR $\alpha$  mRNA, while both PPAR $\beta/\delta$  and PPAR $\alpha$  mRNA will be  
360 overexpressed under the influence of TFEB. This is in accordance with our findings of  
361 increased nuclear protein relative abundance of TFEB and NFAT (Fig.3 h and i), with a  
362 consequent larger increase in PPAR $\alpha$  and PPAR $\beta/\delta$  gene expression only in the twice-a-  
363 day approach (Fig.5 c and d). Thus, our results indicate that the twice-a-day training  
364 might be more effective to induce adaptations in fat metabolism.

365

366 It has been suggested that the greater exercise-induced upregulation of cell  
367 signalling pathways with the train-low approach may be due to enhanced activation of  
368 AMPK and p38 MAPK<sup>19, 2119, 2119, 2119, 21</sup>, but contradictory results have been reported<sup>17,</sup>  
369 <sup>19, 21, 53</sup>. For example, Cochran et al.<sup>21</sup> observed larger increases in p-p38 MAPK but not  
370 p-AMPK, while Yeo et al.<sup>19</sup> reported larger increases in p-AMPK but without  
371 alterations in p-p38 MAPK, with the train-low approach. On the other hand, Gejl et al.<sup>53</sup>  
372 and Psilander et al.<sup>17</sup> found no effect of their train-low approaches on both p-AMPK and  
373 p-p38 MAPK protein content, which is consistent with our findings (Fig. 2g-i). There  
374 are no obvious explanations for these contradictory results, although muscle glycogen  
375 content before the second exercise session did differ between studies (~170 mmol·kg<sup>-1</sup>·dry mass<sup>17</sup>,  
376 ~250 mmol·kg<sup>-1</sup>·dry mass<sup>19</sup>, ~300 mmol·kg<sup>-1</sup>·dry mass<sup>21</sup>, ~400 mmol·kg<sup>-1</sup>·dry mass<sup>53</sup>,  
377 ~250 mmol·kg<sup>-1</sup>·dry mass in the present study). The “train-low” protocols

378 used in each study also differed and consisted of either a prolonged exercise followed  
379 by a moderate-intensity interval exercise 14h later<sup>17</sup>, a prolonged exercise followed by a  
380 HIIE two hours later<sup>19</sup>, two HIIE performed three hours apart<sup>21</sup>, or a HIIE followed by a  
381 prolonged exercise seven hours later<sup>53</sup>. However, activation of AMPK and p38 MAPK  
382 does not seem to be associated with muscle glycogen levels or a particular train-low  
383 regime.

384

385 In contrast to our results, two studies have reported greater exercise-induced  
386 increases in genes associated with mitochondrial biogenesis (e.g., PGC-1 $\alpha$ ) with the  
387 once-daily approach (~5-fold) compared to a control condition (~2- to 4-fold;<sup>14, 17</sup>). In  
388 the present study, PGC-1 $\alpha$  increased similarly between the once-daily and the control  
389 condition (~5-fold). However, one notable difference is that pre-exercise muscle  
390 glycogen levels were lower in these previous two studies (105 and 170 mmol·kg<sup>-1</sup>·dry  
391 mass, respectively), compared with the current study (~250 mmol·kg<sup>-1</sup>·dry mass).  
392 Nonetheless, this appears unlikely to explain the contrasting findings as all three studies  
393 had pre-exercise muscle glycogen levels between 100 and 300 mmol·kg<sup>-1</sup>·dry mass,  
394 which has been hypothesised to be a critical level to enhance exercise-induced  
395 molecular signalling<sup>31</sup>.

396

397 In summary, our findings indicate that the greater exercise-induced signalling  
398 with the so-called “train-low” approach can mostly be attributed to the performance of  
399 two exercise sessions in close succession rather than exercising with a reduced muscle  
400 glycogen content. We presented evidence that performing two exercise sessions  
401 separated by a short recovery period increases the nuclear abundance of TFEB and  
402 NFAT and potentiates the transcription of PGC-1 $\alpha$ , PPAR $\alpha$  and PPAR $\beta/\delta$ . Although we



403 have identified novel molecular mechanism by which the twice-a-day approach might  
404 be a more effective strategy to induce adaptations related to mitochondrial biogenesis  
405 and fat oxidation, further research is required to determine if training using the twice-a-  
406 day approach results in greater changes in mitochondrial content and function and fat  
407 oxidation.

408

409

## 410 **Methods**

### 411 **Participants**

412 Eight healthy, physically-active men, who were accustomed to cycling [age:  
413  $30.8 \pm 3.5$  years, body mass:  $78.7 \pm 9.9$  kg, height:  $1.76 \pm 0.07$  m, body fat:  $13.6 \pm$   
414  $5.1\%$ , maximal oxygen uptake ( $\dot{V}O_{2\max}$ ):  $37.1 \pm 6.4$  mL·kg<sup>-1</sup>·min<sup>-1</sup>, maximal aerobic  
415 power (MAP):  $229.6 \pm 38.2$  W, and first (LT1) and second (LT2) lactate thresholds:  
416  $78.1 \pm 20.9$  and  $170.0 \pm 37.7$  W, respectively] participated in this study. Participants  
417 were informed about the procedures, risks, and benefits associated with the protocol,  
418 before they signed a consent form agreeing to participate in this study, which was  
419 approved by the Research Ethics Committee of Federal University of Pernambuco. The  
420 study was conducted according to the principles presented in the Declaration of  
421 Helsinki.

422

423

### 424 **Study overview**

425 Each participant completed three experimental trials in a randomized, crossover  
426 design. An overview of the experimental design is shown in Fig. 8. Briefly, in the once-  
427 daily approach participants performed the muscle glycogen-depleting exercise in the

428 evening before (2000 – 2200 h) followed by an overnight fast. On the experimental day  
429 morning (0800 h), participants ate a low-CHO breakfast (CHO:  $42.7 \pm 5.0$  kcal, 7%; fat:  
430  $365.9 \pm 43.1$  kcal, 60%; protein:  $201.3 \pm 23.7$  kcal, 33%) and performed the HIIE  
431 session (1300 h). In the twice-a-day approach, participants ate a low-CHO breakfast on  
432 the morning of the experimental day (0800 h), and then performed a muscle glycogen-  
433 depleting exercise (0900-1100 h), followed by a 2-h rest period and a HIIE (1300 h).  
434 During the control, participants consumed the same low-CHO breakfast as in both  
435 experimental trials (0800 h), and then performed the same HIIE session (i.e., 1300 h).  
436 Water was provided ad libitum throughout the experiments. Skeletal muscle biopsies  
437 from the *vastus lateralis* and venous blood samples were taken before, immediately  
438 after, and 3 h after completion of the HIIE sessions. Each experimental trial was  
439 separated by approximately two weeks to washout any residual effect of fatigue or  
440 damage caused by exercise and the multiple muscle biopsies.

441

## 442 **Exercise protocols**

### 443 *Preliminary test*

444 One week prior to the commencement of this study, participants performed a  
445 graded exercise test to volitional fatigue on a cycloergometer (Ergo-Fit 167, Pirmasens,  
446 Germany). The test commenced at 50 W, and thereafter intensity was increased by 25  
447 W every 4 min, with a 1-min break between stages, until volitional exhaustion<sup>54</sup>. The  
448 test was interrupted when the participant could no longer maintain the required cadence  
449 (70 rpm). Strong verbal encouragement was provided to each participant.

450

451  $\dot{V}O_2$  was measured breath-by-breath throughout the test using an automatic  
452 analyzer (Cortex, Metalyzer 3B<sup>®</sup>, Saxony, Germany). Before each test, the gas analyzer

453 was calibrated using ambient air and a cylinder of known gas concentration (12% O<sub>2</sub>  
454 and 5% CO<sub>2</sub>). The volume was calibrated using a 3-L syringe (Quinton Instruments,  
455 Washington, US). Capillary ear lobe blood samples were taken at rest and immediately  
456 after each 4-min stage of the test for determination of plasma lactate concentration. The  
457 LT1 was visually identified by two experienced investigators as the first increase in  
458 plasma lactate concentration above resting level. The LT2 was calculated by the  
459 modified Dmax method<sup>55</sup>. This was determined by the point on the polynomial  
460 regression curve that yields the maximal perpendicular distance to the straight line  
461 connecting the LT1 and the final stage of the test.  $\dot{V}O_{2max}$  was defined as the highest 30-  
462 s average VO<sub>2</sub> during the test and MAP was determined as the highest workload  
463 reached. If a participant did not complete the final 4-min stage, then the MAP was  
464 determined using the following equation:

465

$$466 \quad \text{MAP} = \text{PO}_{\text{last}} + (t/240 \cdot 25) \quad (1)$$

467

468 where  $\text{PO}_{\text{last}}$  is the power output in watts of the last completed stage performed by the  
469 participant,  $t$  is the time (in seconds) sustained during the last incomplete stage, and 25  
470 corresponds to the increments in power (Watts) at each stage.

471

#### 472 *Muscle glycogen-depleting exercise*

473 To reduce muscle glycogen stores, participants cycled for 100 min at a power  
474 output corresponding to 50% of the difference between LT1 and LT2 ( $124 \pm 27$  W,  $54 \pm$   
475 5% of MAP). Then, after an 8-min rest, participants performed six 1-min exercise bouts  
476 at 125% MAP ( $287 \pm 46$  W) interspersed with 1-min rest periods<sup>56</sup>. This protocol has  
477 been shown effective for reducing the muscle glycogen content<sup>57,58</sup>.

478

479

480 *High-intensity interval exercise*

481           The HIIE sessions were preceded by a 5-min warm-up at 90% LT1. Participants  
482 completed ten 2-min intervals at an intensity of 20% of the difference between the LT2  
483 and MAP ( $182 \pm 38$  W,  $79 \pm 5\%$  of MAP). Each 2-min bout was interspersed with a 1-  
484 min passive recovery period<sup>54</sup>. Participants were required to maintain a pedal frequency  
485 of 70-80 rpm during each 2-min bout. The  $\dot{V}O_2$ , carbon dioxide production, RER, and  
486  $\dot{V}E$  were measured breath-by-breath throughout each HIIE session using the same gas  
487 analyzer described for the graded exercise test. Data were then converted to 30-s  
488 intervals for further analysis.

489

490 **Diet and exercise control before starting experimental manipulation**

491           Participants were asked to register all foods and beverages consumed during the  
492 48-h preceding the start of the first experimental trial (Fig. 8). Dinner of two days  
493 before, and breakfast, lunch and dinner of one day before the experimental trial were  
494 replicated during the subsequent experimental trials (Fig. 8). They were given verbal  
495 and written instructions on how to repeat this before the subsequent experimental  
496 approach. Checklists were used to check any deviations from the menu. Participants  
497 were also instructed to avoid any strenuous exercise as well as alcohol and caffeine  
498 consumption for the 24 h prior to each experimental trial.

499

500

501

502 **Blood collection and analysis**

503 Blood samples were collected from an antecubital vein and separated into three  
504 different tubes. Two millilitres of blood were collected in tubes containing sodium  
505 fluoride and EDTA (Hemogard<sup>TM</sup> Fluoride/EDTA, BD Vacutainer<sup>®</sup>, USA). Blood was  
506 centrifuged at 4,000 rev.min<sup>-1</sup> for 10 min at 4° C with the resulting plasma transferred to  
507 2-mL tubes and immediately analysed for plasma glucose and lactate concentrations.  
508 Plasma glucose and lactate concentrations were analysed with a commercially available  
509 enzymatic kit (Glucose Liquiform and Enzymatic Lactate, respectively, Labtest, Lagoa  
510 Santa, Minas Gerais, Brazil). A further 8 mL of blood was collected in tubes containing  
511 Clot activator and gel for serum separation (SST II Plus, BD Vacutainer<sup>®</sup>, USA), and  
512 another 3 mL of blood was collected in tubes containing sodium heparin (Sodium  
513 Heparin<sup>N</sup> Plus, BD Vacutainer<sup>®</sup>, USA). Both were then centrifuged at 4,000 rev.min<sup>-1</sup>  
514 for 10 min at 4° C, and the resulting serum/plasma frozen and stored in liquid nitrogen  
515 for later analyses of concentration of FFA and glycerol concentrations, and plasma  
516 catecholamine. Serum FFA and glycerol concentrations were determined by an  
517 enzymatic colorimetric method (EFFA-100 and EGLY-200, BioAssay, Hayward,  
518 California, USA). Plasma catecholamine concentrations were determined by using ion-  
519 pairing reverse phase liquid chromatography coupled with electrochemical detection<sup>56</sup>.

520

### 521 **Muscle tissue samples and analysis**

522 Nine separate incisions (three per trial) were made into the vastus lateralis under  
523 local anaesthesia (2% Xylestesin<sup>®</sup>), and a muscle sample taken using Bergström  
524 needle<sup>59</sup> adapted for manual suction<sup>60</sup>. Samples were taken approximately 1 cm apart  
525 from a previous biopsy site. Samples [mean: 118 ± 48 mg; range: 49 to 248 mg] were  
526 immediately snap-frozen in liquid nitrogen, and then stored at in -80°C until subsequent  
527 analyses. Muscle samples were taken at rest (pre HIIE), immediately after HIIE (post

528 HIIIE) and 3 h after HIIIE (3 h post HIIIE). Biopsies were subsequently analysed for  
529 muscle glycogen content, as well as gene and protein expression (described  
530 subsequently).

531

### 532 **Muscle glycogen concentration**

533        Approximately 2 to 3 mg of freeze-dried muscle tissue was powdered and  
534 dissected free of all visible non-muscle tissue. Powdered muscle tissue was then  
535 extracted with 250  $\mu$ L of 2 M HCl, incubated at 95°C for 2 h (agitated gently every 20  
536 min), and then neutralized with 750  $\mu$ L of 0.66 M NaOH. Glycogen concentration was  
537 subsequently assayed in triplicate via enzymatic analysis with fluorometric detection<sup>61</sup>  
538 and the mean value reported as millimoles per kilogram dry weight.

539

### 540 **Western blotting**

#### 541 *Muscle homogenate preparations and protein assays*

542        Approximately 20 mg of frozen muscle tissue was homogenized using a  
543 TissueLyser II (Qiagen, Valencia, CA) in a 1:20 dilution of ice-cold RIPA buffer (pH  
544 7.4) containing: 0.15 M NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 0.05 M  
545 Tris, 0.1% SDS, 0.1 M EDTA, 1% protease/phosphatase inhibitor cocktail (100X, Cell  
546 Signalling Technology [CST], #5872, St. Louis, MI). Homogenates were rotated end-  
547 over-end for 60 min at 4°C. Protein content of muscle homogenate was measured in  
548 triplicate using a Bradford assay (Bio-Rad protein assay dye reagent concentrate, Bio-  
549 Rad Laboratories, Hercules, CA) against bovine serum albumin standards (BSA,  
550 A9647, Sigma-Aldrich). Nuclear and crude cytosolic fractions were prepared from 40 to  
551 60 mg of wet muscle using a commercially-available nuclear extraction kit (NE-PER,  
552 Pierce, USA). Muscle samples were homogenized in CER-I buffer containing a

553 protease/phosphatase inhibitor cocktail (CST #5872). Following centrifugation, the  
554 supernatant was taken and pellets containing nuclei were washed five times in PBS to  
555 remove cytosolic contamination, before nuclear proteins were extracted by  
556 centrifugation in high-salt NER buffer supplemented with the same inhibitors cocktail  
557 following manufacturers' instruction. Sufficient muscle was available to prepare  
558 subcellular fractions from eight participants.

559

560

### 561 *Immunoblotting*

562 RIPA-buffered homogenate was diluted in 4X Laemmli buffer (0.25 M Tris, 8%  
563 SDS, 40% glycerol, 0.04% bromophenol blue, 20% 2-mercaptoethanol) and equal  
564 amounts of total protein (10 to 20  $\mu$ g) were loaded on Criterion™ 4-20% TGX Stain-  
565 Free™ Precast Gels (Bio-Rad). All samples for a participant were loaded in adjacent  
566 lanes on the same gel. Four to six different dilutions of a mixed-homogenate internal  
567 standard were also loaded on each gel and a calibration curve plotted of density against  
568 protein content. From the subsequent linear regression equation protein abundance was  
569 calculated from the measured band intensity for each sample on the gel<sup>62</sup>. Gel  
570 electrophoresis ran for 90 min at 80-150 V. Proteins were turbo-transferred to a 0.2  $\mu$ m  
571 PVDF membrane at 25 V for 10 min. Membranes were blocked for 60 min at room  
572 temperature in 5% non-fat dry milk (NFD) diluted in Tris-buffered saline with 0.1%  
573 Tween-20 (TBST). Membranes were then washed in TBST and incubated overnight at  
574 4°C – with the appropriate primary antibody: monoclonal anti-PGC-1 $\alpha$  (CST #2178),  
575 polyclonal anti-p-ACC<sup>Ser79</sup> (CST #3361), polyclonal anti-AMPK (CST #2532),  
576 polyclonal anti-p-AMPK<sup>Thr172</sup> (CST #2531), polyclonal anti-p38 MAPK (CST #9212),  
577 polyclonal anti-p-p38 MAPK<sup>Thr180/Tyr182</sup> (CST #9211), PHF20 (CST #3934), p53 (CST

578 #2527), NFAT2 (CST #8032) and Phospho-(Ser) 14-3-3 Binding Motif Antibody anti-  
579 TFEB (CST #9601) diluted (1:1,000) in 5% BSA and 0.02% sodium azide in TBST.  
580 Following TBST washes the membranes were incubated in the relevant secondary  
581 antibody: Goat anti-rabbit IgG (Perkin Elmer/ NEF812001EA), diluted (1:10,000) in  
582 5% NFD in TBST, for 60 min at room temperature. After further washes, membranes  
583 were incubated in chemiluminescent solution (1.25 mM 294 luminol, 0.2 mM  $\rho$ -  
584 coumaric acid, 100 mM Tris pH 8.5, 0.009%  $H_2O_2$ ) for 2 min and images were taken  
585 with a ChemiDoc Imaging System fitted (Bio-Rad). Densitometry was performed with  
586 Image Lab 5.0 software (Bio-Rad). Images are typically displayed with at least five  
587 bandwidths above and below the band of interest.

588

### 589 **Real-Time quantitative PCR**

#### 590 *RNA extraction*

591 Total RNA from approximately 10 to 15 mg of frozen muscle was homogenized  
592 in 800  $\mu$ L of TRIzol reagent (Thermo Fisher Scientific, Waltham, USA) using a  
593 TissueLyser II (Qiagen, Valencia, CA)<sup>63</sup>. The concentration and purity of each sample  
594 was assessed using a NanoDrop One/One<sup>c</sup> (Thermo Fisher Scientific). As  
595 representative, RNA integrity of a subset of samples was measured using a Bio-Rad  
596 Experion microfluidic gel electrophoresis system (7007104, Experion RNA StdSens  
597 Analysis kit) and determined from the RNA quality indicator. RNA was stored at  $-80^\circ\text{C}$   
598 until reverse-transcription was performed.

599

#### 600 *Reverse transcription*

601 1  $\mu$ g RNA, in a total reaction volume of 20  $\mu$ L, was reverse-transcribed to  
602 cDNA using a Thermocycler (S1000, Bio-Rad) and Bio-Rad iScript RT Supermix (170-



603 8840) per the manufacturer's instructions. Priming was performed at 25°C for 5 min  
604 and reverse transcription for 30 min at 42°C. All samples, including RT-negative  
605 controls, were performed during the same run. cDNA was stored at -20°C until  
606 subsequent analysis.

607

### 608 *qPCR*

609 Relative mRNA expression was measured by qPCR (QuantStudio 7 Flex,  
610 Applied Biosystems, Foster City, CA) using SsoAdvanced Universal SYBR Green  
611 Supermix (Bio-Rad). Primers were designed using Primer-BLAST<sup>64</sup> to include all splice  
612 variants, and were purchased from Sigma-Aldrich (see Supplementary Table 1 for  
613 primer details). All reactions were performed in duplicate on 384-well MicroAmp  
614 optical plates (4309849, Applied Biosystems) using an epMotion M5073 automated  
615 pipetting system (Eppendorf AG). Total reaction volume of 5 µL contained 2 µL of  
616 diluted cDNA template, 2.5 µL of mastermix, and 0.3 µM or 0.9 µM primers. All assays  
617 ran for 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. The  
618 stability of six potential reference genes were determined by *BestKeeper*<sup>65</sup> and  
619 *NormFinder*<sup>66</sup> software, and the three most stably expressed genes were TBP, 18S, and  
620 ACTB (Supplementary Table 1). There were no main effects of training approach, time,  
621 nor interaction effects, for the Ct values of the three most stable housekeeping genes ( $P$   
622  $> 0.05$ ). Expression of each target gene was normalized to the geometric mean of  
623 expression of the three reference genes<sup>67</sup>, and using the  $2^{-\Delta\Delta Ct}$  method (where Ct is the  
624 quantification cycle)<sup>68</sup>.

625

### 626 **Statistical analysis**

627 Statistical analysis was performed using the GraphPad Prism software version  
628 6.01. All data were checked for normality with the Kolomogorov-Smirnov test. To  
629 compare the responses before, immediately after, and 3 h after each HIIE session, data  
630 were analysed with two-way repeated measures ANOVA (exercising approach vs.  
631 time). A Bonferroni's post-hoc test was used to locate the differences. All values are  
632 expressed as means  $\pm$  SD. Significance was accepted when  $p < 0.05$ .

633

### 634 **Acknowledgements**

635 This work was supported by the Brazilian National Council for Scientific and  
636 Technological Development (Special visitor researcher of science without borders  
637 program, process N° 406201/2013-7). V.A. Andrade-Souza is grateful to the Foundation  
638 for the Support of Science and Technology of the State of Pernambuco (FACEPE) for  
639 his scholarship. We thank X. Yan, C. Granata, A.J. Genders, E.C. Marin, R. Aragão and  
640 C.R. Correia-Oliveira for technical assistance.

641

### 642 **Author contributions**

643 V. A. A-S., R. B., D. J. B., and A. E. L-S. designed the experiments. V. A. A-S., T. G.,  
644 A. S., K. A. S. S., F. T., L. A., and A. E. L-S. performed the experiments. V. A. A-S., T.  
645 G., A. S., K. A. S. S., F. T., L. A., and A. E. L-S. conducted the exercise analyses at  
646 Department of Physical Education and Sports Science, Academic Center of Vitoria,  
647 Federal University of Pernambuco and V. A. A-S., J. F., E. P., N. S., and J. K.  
648 conducted qPCR and western blot analyses at Institute for Health and Sport, Victoria  
649 University. V. A. A-S analyzed data and discussed analyses and results with J. F., J. K.,  
650 D. J. B., and A. E. L-S. T.G., K. A. S. S., R. B., and C. G. L. supported data analyses.

651 V. A. A-S., K. A. S. S., J. K., D. J. B., and A. E. L-S made the figures. All authors  
652 wrote and approved the manuscript.

653

654

655 **References**

- 656 1. Granata C, Oliveira RS, Little JP, Renner K, Bishop DJ. Training intensity  
657 modulates changes in PGC-1alpha and p53 protein content and mitochondrial  
658 respiration, but not markers of mitochondrial content in human skeletal muscle.  
659 *FASEB J* **30**, 959-970 (2016).
- 660
- 661 2. Granata C, Oliveira RS, Little JP, Renner K, Bishop DJ. Sprint-interval but not  
662 continuous exercise increases PGC-1alpha protein content and p53  
663 phosphorylation in nuclear fractions of human skeletal muscle. *Sci Rep* **7**, 44227  
664 (2017).
- 665
- 666 3. Holloszy JO. Biochemical adaptations in muscle. Effects of exercise on  
667 mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle.  
668 *J Biol Chem* **242**, 2278-2282 (1967).
- 669
- 670 4. Hood DA, Tryon LD, Carter HN, Kim Y, Chen CC. Unravelling the  
671 mechanisms regulating muscle mitochondrial biogenesis. *Biochem J* **473**, 2295-  
672 2314 (2016).
- 673
- 674 5. Little JP, Safdar A, Bishop D, Tarnopolsky MA, Gibala MJ. An acute bout of  
675 high-intensity interval training increases the nuclear abundance of PGC-1alpha  
676 and activates mitochondrial biogenesis in human skeletal muscle. *Am J Physiol*  
677 *Regul Integr Comp Physiol* **300**, R1303-1310 (2011).

678

679 6. Granata C, Jamnick NA, Bishop DJ. Principles of Exercise Prescription, and  
680 How They Influence Exercise-Induced Changes of Transcription Factors and  
681 Other Regulators of Mitochondrial Biogenesis. *Sports Med* **48**, 1541-1559  
682 (2018).

683

684 7. Granata C, Jamnick NA, Bishop DJ. Training-Induced Changes in  
685 Mitochondrial Content and Respiratory Function in Human Skeletal Muscle.  
686 *Sports Med* **48**, 1809-1828 (2018).

687

688 8. Granata C, Oliveira RS, Little JP, Renner K, Bishop DJ. Mitochondrial  
689 adaptations to high-volume exercise training are rapidly reversed after a  
690 reduction in training volume in human skeletal muscle. *FASEB J* **30**, 3413-3423  
691 (2016).

692

693 9. Islam H, Edgett BA, Gurd BJ. Coordination of mitochondrial biogenesis by  
694 PGC-1alpha in human skeletal muscle: a re-evaluation. *Metabolism*, (2017).

695

696 10. Baar K, Mcgee S. Optimizing training adaptations by manipulating glycogen.  
697 *Eur J Sport Sci* **8**, 97-106 (2008).

698

699 11. Bartlett JD, Hawley JA, Morton JP. Carbohydrate availability and exercise  
700 training adaptation: Too much of a good thing? *Eur J Sport Sci* **15**, 3-12 (2015).

701

702 12. Knuiman P, Hopman MTE, Mensink M. Glycogen availability and skeletal  
703 muscle adaptations with endurance and resistance exercise. *Nutr Metab* **12**,  
704 (2015).

705

706 13. Pilegaard H, Osada T, Andersen LT, Helge JW, Saltin B, Neufer PD. Substrate  
707 availability and transcriptional regulation of metabolic genes in human skeletal  
708 muscle during recovery from exercise. *Metabolism* **54**, 1048-1055 (2005).

709

710 14. Bartlett JD, *et al.* Reduced carbohydrate availability enhances exercise-induced  
711 p53 signaling in human skeletal muscle: implications for mitochondrial  
712 biogenesis. *Am J Physiol-Reg I* **304**, R450-R458 (2013).

713

714 15. Lane SC, *et al.* Effects of sleeping with reduced carbohydrate availability on  
715 acute training responses. *J Appl Physiol (1985)* **119**, 643-655 (2015).

716

717 16. Pilegaard H, *et al.* Influence of pre-exercise muscle glycogen content on  
718 exercise-induced transcriptional regulation of metabolic genes. *J Physiol-*  
719 *London* **541**, 261-271 (2002).

720

721 17. Psilander N, Frank P, Flockhart M, Sahlin K. Exercise with low glycogen  
722 increases PGC-1 alpha gene expression in human skeletal muscle. *Eur J Appl*  
723 *Physiol* **113**, 951-963 (2013).

724

725 18. Hulston CJ, *et al.* Training with Low Muscle Glycogen Enhances Fat  
726 Metabolism in Well-Trained Cyclists. *Med Sci Sports Exerc* **42**, 2046-2055  
727 (2010).

728

729 19. Yeo WK, *et al.* Acute signalling responses to intense endurance training  
730 commenced with low or normal muscle glycogen. *Exp Physiol* **95**, 351-358  
731 (2010).

732

733 20. Yeo WK, Paton CD, Garnham AP, Burke LM, Carey AL, Hawley JA. Skeletal  
734 muscle adaptation and performance responses to once a day versus twice every  
735 second day endurance training regimens. *J Appl Physiol (1985)* **105**, 1462-1470  
736 (2008).

737

738 21. Cochran AJR, Little JP, Tarnopolsky MA, Gibala MJ. Carbohydrate feeding  
739 during recovery alters the skeletal muscle metabolic response to repeated  
740 sessions of high-intensity interval exercise in humans. *J Appl Physiol (1985)*  
741 **108**, 628-636 (2010).

742

743 22. Cochran AJR, *et al.* Manipulating Carbohydrate Availability Between Twice-  
744 Daily Sessions of High-Intensity Interval Training Over 2 Weeks Improves  
745 Time-Trial Performance. *Int J Sport Nutr Exerc Metab* **25**, 463-470 (2015).

746

- 747 23. Gejl KD, *et al.* No Superior Adaptations to Carbohydrate Periodization in Elite  
748 Endurance Athletes. *Med Sci Sports Exerc* **49**, 2486-2497 (2017).
- 749
- 750 24. Morton JP, *et al.* Reduced carbohydrate availability does not modulate training-  
751 induced heat shock protein adaptations but does upregulate oxidative enzyme  
752 activity in human skeletal muscle. *J Appl Physiol (1985)* **106**, 1513-1521 (2009).
- 753
- 754 25. Hansen AK, Fischer CP, Plomgaard P, Andersen JL, Saltin B, Pedersen BK.  
755 Skeletal muscle adaptation: training twice every second day vs. training once  
756 daily. *J Appl Physiol (1985)* **98**, 93-99 (2005).
- 757
- 758 26. Gibala MJ, McGee SL, Garnham AP, Howlett KF, Snow RJ, Hargreaves M.  
759 Brief intense interval exercise activates AMPK and p38 MAPK signaling and  
760 increases the expression of PGC-1alpha in human skeletal muscle. *J Appl*  
761 *Physiol (1985)* **106**, 929-934 (2009).
- 762
- 763 27. Pilegaard H, Ordway GA, Saltin B, Neufer PD. Transcriptional regulation of  
764 gene expression in human skeletal muscle during recovery from exercise. *Am J*  
765 *Physiol-Endoc M* **279**, E806-E814 (2000).
- 766
- 767 28. Russell AP, Hesselink MK, Lo SK, Schrauwen P. Regulation of metabolic  
768 transcriptional co-activators and transcription factors with acute exercise.  
769 *FASEB J* **19**, 986-988 (2005).



770

771 29. McGinley C, Bishop DJ. Distinct protein and mRNA kinetics of skeletal muscle  
772 proton transporters following exercise can influence interpretation of adaptations  
773 to training. *Exp Physiol* **101**, 1565-1580 (2016).

774

775 30. Fyfe JJ, Bishop DJ, Zacharewicz E, Russell AP, Stepto NK. Concurrent exercise  
776 incorporating high-intensity interval or continuous training modulates mTORC1  
777 signaling and microRNA expression in human skeletal muscle. *Am J Physiol*  
778 *Regul Integr Comp Physiol* **310**, R1297-1311 (2016).

779

780 31. Impey SG, *et al.* Fuel for the work required: A theoretical framework for  
781 carbohydrate periodization and the glycogen threshold hypothesis. *Sports Med*  
782 **48**, 1031-1048 (2018).

783

784 32. Mansueto G, *et al.* Transcription Factor EB Controls Metabolic Flexibility  
785 during Exercise. *Cell Metab* **25**, 182-196 (2017).

786

787 33. Long YC, Glund S, Garcia-Roves PM, Zierath JR. Calcineurin regulates skeletal  
788 muscle metabolism via coordinated changes in gene expression. *J Biol Chem*  
789 **282**, 1607-1614 (2007).

790

791 34. Masuda ES, Imamura R, Amasaki Y, Arai K, Arai N. Signalling into the T-cell  
792 nucleus: NFAT regulation. *Cell Signal* **10**, 599-611 (1998).

793

794 35. Settembre C, *et al.* TFEB controls cellular lipid metabolism through a  
795 starvation-induced autoregulatory loop. *Nat Cell Biol* **15**, 647-658 (2013).

796

797 36. Baar K. Nutrition and the adaptation to endurance training. *Sports Med* **44**  
798 **Suppl 1**, S5-12 (2014).

799

800 37. Burke LM. Fueling strategies to optimize performance: training high or training  
801 low? *Scand J Med Sci Sports* **20 Suppl 2**, 48-58 (2010).

802

803 38. Hawley JA, Burke LM. Carbohydrate Availability and Training Adaptation:  
804 Effects on Cell Metabolism. *Exerc Sport Sci Rev* **38**, 152-160 (2010).

805

806 39. Philp A, Burke LM, Baar K. Altering endogenous carbohydrate availability to  
807 support training adaptations. *Nestle Nutr Inst Workshop Ser* **69**, 19-31;  
808 discussion 31-17 (2011).

809

810 40. Vainshtein A, Tryon LD, Pauly M, Hood DA. Role of PGC-1alpha during acute  
811 exercise-induced autophagy and mitophagy in skeletal muscle. *Am J Physiol*  
812 *Cell Physiol* **308**, C710-719 (2015).

813

- 814 41. Wright DC, Han DH, Garcia-Roves PM, Geiger PC, Jones TE, Holloszy JO.  
815 Exercise-induced mitochondrial biogenesis begins before the increase in muscle  
816 PGC-1alpha expression. *J Biol Chem* **282**, 194-199 (2007).
- 817
- 818 42. Macian F. NFAT proteins: key regulators of T-cell development and function.  
819 *Nat Rev Immunol* **5**, 472-484 (2005).
- 820
- 821 43. Medina DL, *et al.* Lysosomal calcium signalling regulates autophagy through  
822 calcineurin and TFEB. *Nat Cell Biol* **17**, 288-299 (2015).
- 823
- 824 44. Perry CGR, Lally J, Holloway GP, Heigenhauser GJF, Bonen A, Spriet LL.  
825 Repeated transient mRNA bursts precede increases in transcriptional and  
826 mitochondrial proteins during training in human skeletal muscle. *J Physiol-  
827 London* **588**, 4795-4810 (2010).
- 828
- 829 45. Leick L, Plomgaard P, Gronlokke L, Al-Abaiji F, Wojtaszewski JF, Pilegaard H.  
830 Endurance exercise induces mRNA expression of oxidative enzymes in human  
831 skeletal muscle late in recovery. *Scand J Med Sci Sports* **20**, 593-599 (2010).
- 832
- 833 46. Yang Y, Creer A, Jemiolo B, Trappe S. Time course of myogenic and metabolic  
834 gene expression in response to acute exercise in human skeletal muscle. *J Appl  
835 Physiol (1985)* **98**, 1745-1752 (2005).
- 836

- 837 47. Koh JH, Hancock CR, Terada S, Higashida K, Holloszy JO, Han DH. PPARbeta  
838 Is Essential for Maintaining Normal Levels of PGC-1alpha and Mitochondria  
839 and for the Increase in Muscle Mitochondria Induced by Exercise. *Cell Metab*  
840 **25**, 1176-1185 e1175 (2017).
- 841
- 842 48. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of  
843 skeletal muscle adaptation. *Cell Metab* **17**, 162-184 (2013).
- 844
- 845 49. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise  
846 and their metabolic consequences. *J Appl Physiol Respir Environ Exerc Physiol*  
847 **56**, 831-838 (1984).
- 848
- 849 50. MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the  
850 role of exercise intensity. *J Physiol* **595**, 2915-2930 (2017).
- 851
- 852 51. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative biology of  
853 exercise. *Cell* **159**, 738-749 (2014).
- 854
- 855 52. Kessen U, Schaloske R, Aichele A, Mutzel R. Ca(2+)/calmodulin-independent  
856 activation of calcineurin from Dictyostelium by unsaturated long chain fatty  
857 acids. *J Biol Chem* **274**, 37821-37826 (1999).
- 858

- 859 53. Gejl KD, *et al.* Changes in metabolism but not myocellular signaling by training  
860 with CHO-restriction in endurance athletes. *Physiol Rep* **6**, e13847 (2018).
- 861
- 862 54. Edge J, Bishop D, Goodman C. Effects of chronic NaHCO<sub>3</sub> ingestion during  
863 interval training on changes to muscle buffer capacity, metabolism, and short-  
864 term endurance performance. *J Appl Physiol (1985)* **101**, 918-925 (2006).
- 865
- 866 55. Bishop D, Jenkins DG, Mackinnon LT. The relationship between plasma lactate  
867 parameters, W-peak and 1-h cycling performance in women. *Med Sci Sports*  
868 *Exerc* **30**, 1270-1275 (1998).
- 869
- 870 56. Lima-Silva AE, *et al.* Effects of a low- or a high-carbohydrate diet on  
871 performance, energy system contribution, and metabolic responses during  
872 supramaximal exercise. *Appl Physiol Nutr Metab* **38**, 928-934 (2013).
- 873
- 874 57. Gollnick PD, Piehl K, Saltin B. Selective glycogen depletion pattern in human  
875 muscle fibres after exercise of varying intensity and at varying pedalling rates. *J*  
876 *Physiol-London* **241**, 45-57 (1974).
- 877
- 878 58. Heigenhauser GJ, Sutton JR, Jones NL. Effect of glycogen depletion on the  
879 ventilatory response to exercise. *J Appl Physiol Respir Environ Exerc Physiol*  
880 **54**, 470-474 (1983).

881

- 882 59. Bergström J. Muscle electrolytes in man determined by neutron activation  
883 analysis on needle biopsy specimens. *Scand J Clin Lab Invest* **14**, 1-110 (1962).
- 884
- 885 60. Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy  
886 maximizes sample size. *Med Sci Sports Exerc* **14**, 101-102 (1982).
- 887
- 888 61. Harris RC, Hultman E, Nordesjo LO. Glycogen, glycolytic intermediates and  
889 high-energy phosphates determined in biopsy samples of musculus quadriceps  
890 femoris of man at rest. Methods and variance of values. *Scand J Clin Lab Invest*  
891 **33**, 109-120 (1974).
- 892
- 893 62. Murphy RM, Lamb GD. Important considerations for protein analyses using  
894 antibody based techniques: down-sizing Western blotting up-sizes outcomes. *J*  
895 *Physiol-London* **591**, 5823-5831 (2013).
- 896
- 897 63. Kuang J, Yan X, Genders AJ, Granata C, Bishop DJ. An overview of technical  
898 considerations when using quantitative real-time PCR analysis of gene  
899 expression in human exercise research. *PloS one* **13**, e0196438 (2018).
- 900
- 901 64. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-  
902 BLAST: a tool to design target-specific primers for polymerase chain reaction.  
903 *BMC bioinformatics* **13**, 134 (2012).
- 904

- 905 65. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable  
906 housekeeping genes, differentially regulated target genes and sample integrity:  
907 BestKeeper--Excel-based tool using pair-wise correlations. *Biotechnol Letters*  
908 **26**, 509-515 (2004).
- 909
- 910 66. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative  
911 reverse transcription-PCR data: a model-based variance estimation approach to  
912 identify genes suited for normalization, applied to bladder and colon cancer data  
913 sets. *Cancer Res* **64**, 5245-5250 (2004).
- 914
- 915 67. Vandesompele J, *et al.* Accurate normalization of real-time quantitative RT-PCR  
916 data by geometric averaging of multiple internal control genes. *Genome Biol* **3**,  
917 (2002).
- 918
- 919 68. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C-  
920 T method. *Nat Protoc* **3**, 1101-1108 (2008).
- 921
- 922 69. Ruas JL, *et al.* A PGC-1alpha isoform induced by resistance training regulates  
923 skeletal muscle hypertrophy. *Cell* **151**, 1319-1331 (2012).
- 924
- 925

926 **Figure legends**

927 **Figure 1 | Muscle glycogen concentration pre, post, and 3 h post the high-intensity**  
928 **interval exercise (HIIE).** Data are presented as mean  $\pm$  standard deviation.  $n = 8$ . \*  
929 significantly lower than control at the same time point ( $P < 0.05$ ); # significantly lower  
930 than pre HIIE for the same condition ( $P < 0.05$ ). Two-way analysis of variance  
931 (ANOVA) with Bonferroni post hoc test.

932 **Figure 2 | Cytosolic protein relative abundance pre and post the high-intensity**  
933 **interval exercise (HIIE).** (a) Representative immunoblots corresponding to total and  
934 phosphorylated protein relative abundance measured in the cytosolic fraction, pre and  
935 post the HIIE in the control, twice-a-day, and once-daily approaches; (b) cytosolic  
936 peroxisome proliferator-activated receptor- $\gamma$  coactivator-1 (PGC-1 $\alpha$ ); (c) cytosolic p53  
937 (p53); (d) cytosolic phosphorylated p53 (p-p53<sup>Ser15</sup>); (e) cytosolic PHF20 (PHF20); (f)  
938 cytosolic phosphorylated 5' adenosine monophosphate-activated protein kinase (p-  
939 AMPK<sup>Thr172</sup>); (g) cytosolic phosphorylated p38 mitogen-activated protein kinase (p-  
940 p38MAPK); (h) cytosolic transcription elongation factor EB (TFEB); (i) cytosolic  
941 nuclear factor of activated T cells (NFAT).  $n = 8$  for all proteins. Data are presented as  
942 fold changes from control pre (mean  $\pm$  standard deviation). # significantly higher than  
943 pre HIIE for the same condition ( $P < 0.05$ ). Two-way analysis of variance (ANOVA)  
944 with Bonferroni post hoc test.

945 **Figure 3 | Nuclear protein relative abundance pre and post the high-intensity**  
946 **interval exercise (HIIE).** (a) Representative immunoblots corresponding to total and  
947 phosphorylated protein relative abundance measured in the nuclear fraction, pre and  
948 post the HIIE in the control, twice-a-day, and once-daily approaches; (b) nuclear  
949 peroxisome proliferator-activated receptor- $\gamma$  coactivator-1 (PGC-1 $\alpha$ ); (c) nuclear p53  
950 (p53); (d) nuclear phosphorylated p53 (p-p53<sup>Ser15</sup>); (e) nuclear PHF20 (PHF20); (f)



951 nuclear phosphorylated AMPKThr172 (p-AMPK<sup>Thr172</sup>); (g) nuclear phosphorylated  
952 p38MAPK (p-p38MAPK); (h) nuclear transcription elongation factor EB (TFEB); (i)  
953 nuclear factor of activated T cells (NFAT). n = 8 for all proteins. Data are presented as  
954 fold changes from control pre (mean ± standard deviation). \* significantly higher than  
955 the once-daily and control condition at the same time point (P < 0.05); † significantly  
956 higher than the once-daily condition at the same time point (P < 0.05). # significantly  
957 higher than pre HIIE for the same condition (P < 0.05). Two-way analysis of variance  
958 (ANOVA) with Bonferroni post hoc test.

959 **Figure 4 | Mitochondrial-related gene expression pre, post, and 3 h post the high-**  
960 **intensity interval exercise (HIIE).** (a) peroxisome proliferator-activated receptor-γ  
961 coactivator-1 (PGC-1α) total gene expression; (b) PGC-1α isoform 1 gene expression;  
962 (c) PGC-1α isoform 4 gene expression; (d) p53 (p53) gene expression; (e) transcription  
963 elongation factor EB (TFEB) gene expression; (f) Chromodomain-helicase-DNA-  
964 binding protein 4 (CHCHD4) gene expression; (g) p21 protein (p21) gene expression;  
965 (h) mitochondrial transcription factor A (Tfam) gene expression; (i) NADH  
966 dehydrogenase (NDUFβ) (mitochondrial complex I) gene expression; (j) succinate  
967 dehydrogenase subunit β (SDHβ) (mitochondrial complex II) gene expression; (k)  
968 cytochrome c (mitochondrial complex III) gene expression; (l) cytochrome c oxidase  
969 subunit IV (COXIV) (mitochondrial complex III) gene expression. n = 8 for all genes  
970 (except Tfam, n = 7). Data are presented as fold changes from control pre (mean ±  
971 standard deviation). \* significantly higher than the once-daily and control condition at  
972 the same time point (P < 0.05); # significantly higher than pre HIIE for the same  
973 condition (P < 0.05); □ significantly higher than post HIIE for the same condition (P <  
974 0.05). Two-way analysis of variance (ANOVA) with Bonferroni post hoc test.


975 **Figure 5 | Genes related to fat transport and lipolysis pre, post, and 3 h post the**  
976 **high-intensity interval exercise (HIIE).** (a) carnitine palmitoyltransferase I (CPT1)  
977 gene expression; (b) mitochondrial uncoupling protein 3 (UCP3) gene expression; (c)  
978 peroxisome proliferator-activated receptor  $\alpha$  (PPAR $\alpha$ ) gene expression; (d) peroxisome  
979 proliferator-activated receptor  $\beta/\delta$  (PPAR $\beta/\delta$ ) gene expression; (e) peroxisome  
980 proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) gene expression; (f) citrate synthase (CS)  
981 gene expression; (g)  $\beta$ -hydroxyacyl-CoA dehydrogenase ( $\beta$ -HAD) gene expression; (h)  
982 fatty acid translocase cluster of differentiation 36 (CD-36) gene expression.  $n = 8$  for all  
983 genes (except CS and UCP3, where  $n = 7$ ). Data are presented as fold changes from  
984 control pre (mean  $\pm$  standard deviation). \* significantly higher than the once-daily  
985 condition at the same time point ( $P < 0.05$ ); † significantly higher than the control  
986 condition at the same time point ( $P < 0.05$ ); # significantly higher than pre HIIE for the  
987 same condition ( $P < 0.05$ ); □ significantly higher than post HIIE for the same condition  
988 ( $P < 0.05$ ). Two-way analysis of variance (ANOVA) with Bonferroni post hoc test.


989 **Figure 6 | Genes related to carbohydrate metabolism pre, post, and 3 h post the**  
990 **high-intensity interval exercise (HIIE).** (a) phosphofructokinase (PFK) gene  
991 expression; (b) glucose transporter 4 (GLUT4) gene expression; (c) pyruvate  
992 dehydrogenase kinase isoenzyme 4 (PDK4) gene expression.  $n = 8$  for all genes. Data  
993 presented as fold changes from control pre (mean  $\pm$  standard deviation). # significantly  
994 higher than pre HIIE for the same condition ( $P < 0.05$ ). Two-way analysis of variance  
995 (ANOVA) with Bonferroni post hoc test.

996 **Figure 7 | Physiological and systemic responses during the high-intensity interval**  
997 **exercise (HIIE).** (a) Heart rate (HR); (b) Ventilation ( $\dot{V}E$ ); (c) Oxygen uptake ( $\dot{V}O_2$ );  
998 (d) Respiratory exchange ratio (RER).  $n = 8$  for all variables. Data are presented as


999 mean  $\pm$  standard deviation. Time effect has been omitted for clarity. INT: Interval. Two-  
1000 way analysis of variance (ANOVA) with Bonferroni post hoc test.

1001 **Figure 8 | Experimental design.** D, dinner; B, breakfast; L, lunch; MG-DE, muscle  
1002 glycogen-depleting exercise; HIIE, high-intensity interval exercise. Open dashed circles  
1003 indicates that participants replicated their normal diet, while closed circles that  
1004 participants ate a low-carbohydrate (CHO) breakfast [CHO:  $42.7 \pm 5.0$  kcal (~7%), fat:  
1005  $365.9 \pm 43.1$  kcal (~60%), protein:  $201.3 \pm 23.7$  kcal (~33%)]. Black arrows indicate  
1006 time point.





bioRxiv preprint doi: <https://doi.org/10.1101/547489>; this version posted February 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



**a**

Nuclear

Control




Twice-a-day

Once-daily

Pre Post




Pre Post

Pre Post


PGC-1 $\alpha$ 

100 kDa

p53






53 kDa



p-p53<sup>Ser15</sup>

53 kDa

PHF20






100 kDa

p-AMPK<sup>Thr172</sup>



60 kDa

p-p38MAPK




38 kDa

TFEB











60 kDa

NFAT




140 kDa

Control  
 Twice-a-day  
 Once-daily


**b****c****d****e****f****g****h****i**

■ Control  
 ■ Twice-a-day  
 □ Once-daily


**a**



**b**




**c**




bioRxiv preprint doi: <https://doi.org/10.1101/547489>; this version posted February 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


**d**




**e**




**f**




**g**




**h**




**i**




**j**



**k**




**l**




■ Control  
 ■ Twice-a-day  
 □ Once-daily

bioRxiv preprint doi: <https://doi.org/10.1101/547489>; this version posted February 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


**a**




**b**




**c**




**d**




**e**




**f**




**g**







**h**







**a****b****c****d**

### Day 1

Habitual diet  
No Exercise

### Day 2

Habitual diet

### Day 3

Experimental Day

Once-daily

(D)

2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM

(B)

(L)

(D)

MG-DE

(B)

Pre Post

↓ ↓

(HIIE)

3 h Post

↓

8 AM 9 AM 10 AM 11 AM 12 AM 1 PM 2 PM 3 PM 4 PM 5 PM

Twice-a-day

(D)

2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM

(B)

(L)

(D)

MG-DE

(B)

Pre Post

↓ ↓

(HIIE)

↓

8 AM 9 AM 10 AM 11 AM 12 AM 1 PM 2 PM 3 PM 4 PM 5 PM

Control

(D)

2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM

(B)

(L)

(D)

(B)

Pre Post

↓ ↓

(HIIE)

↓

8 AM 9 AM 10 AM 11 AM 12 AM 1 PM 2 PM 3 PM 4 PM 5 PM

**Table 1 | Plasma lactate, glucose, epinephrine and norepinephrine concentrations, and serum free fat acid (FFA) and glycerol concentrations at pre, post and 3 h post the high-intensity interval exercise (HIIE).**

	Pre HIIE	Post HIIE	3 h post HIIE
<b>Plasma</b>			
<b>[Lactate] (mmol·L<sup>-1</sup>)</b>			
<i>Control</i>	1.2 ± 0.7	6.2 ± 2.0 □	1.3 ± 0.4
<i>Once-daily</i>	0.9 ± 0.3	3.9 ± 1.0 □ †	1.2 ± 0.4
<i>Twice-a-day</i>	1.4 ± 0.5	4.0 ± 1.6 □ †	2.0 ± 0.7
<b>[Glucose] (mmol·L<sup>-1</sup>)</b>			
<i>Control</i>	5.2 ± 0.8	5.5 ± 0.9	5.3 ± 0.8
<i>Once-daily</i>	5.2 ± 0.5	5.0 ± 0.8 †	4.8 ± 0.7 † #
<i>Twice-a-day</i>	4.4 ± 0.7 * †	4.8 ± 1.1 □ †	4.3 ± 1.0 * †
<b>[Epinephrine] (pg·mL<sup>-1</sup>)</b>			
<i>Control</i>	32.2 ± 18.4	39.3 ± 22.7	36.7 ± 17.8
<i>Once-daily</i>	56.7 ± 25.4	54.2 ± 25.7	35.8 ± 34.8
<i>Twice-a-day</i>	43.1 ± 13.6	43.7 ± 19.0	36.7 ± 10.4
<b>[Norepinephrine] (pg·mL<sup>-1</sup>)</b>			
<i>Control</i>	68.0 ± 34.6	231.1 ± 141.8 □	120.4 ± 90.3
<i>Once-daily</i>	70.7 ± 33.8	350.6 ± 139.8 □	105.5 ± 77.5
<i>Twice-a-day</i>	76.7 ± 49.1	287.5 ± 147.6 □	113.8 ± 44.6
<b>Serum</b>			
<b>[FFA] (μM)</b>			
<i>Control</i>	194.9 ± 118.2	118.6 ± 72.6	130.3 ± 72.1
<i>Once-daily</i>	155.5 ± 79.9	236.5 ± 151.4	158.0 ± 62.8
<i>Twice-a-day</i>	209.9 ± 125.5 †	260.6 ± 151.3 †	230.4 ± 98.2 †
<b>[Glycerol] (mmol·L<sup>-1</sup>)</b>			
<i>Control</i>	0.105 ± 0.021	0.098 ± 0.025	0.098 ± 0.037
<i>Once-daily</i>	0.090 ± 0.037	0.141 ± 0.022 †	0.100 ± 0.039
<i>Twice-a-day</i>	0.106 ± 0.031	0.169 ± 0.046 †	0.102 ± 0.023

Data are presented as mean ± standard deviation. n = 8 for all variables. \* significantly different from the once-daily at the same time point ( $P < 0.05$ ); † significantly different from the control condition at the same time point ( $P < 0.05$ ); # significantly different from pre HIIE for the same condition ( $P < 0.05$ ); □ significantly different from pre and post HIIE for the same condition, except for glucose that was significantly different only from post HIIE ( $P < 0.05$ ). Two-way analysis of variance (ANOVA) with Bonferroni post hoc test.

**Supplementary Table 1 | Details of PCR primers used for RT-qPCR**

Gene	Primer Efficiency (%)	Forward Sequence	Reverse Sequence
PGC-1 $\alpha$	103.6	5'-CAGCCTCTTTGCCAGATCTT-3'	5'-TCACTGCACCACTTGAGTCCAC-3'
PGC-1 $\alpha$ 1	102.9	5'-ATGGAGTGACATCGAGTGTGCT-3'	5'-GAGTCCACCCAGAAAGCTGT-3'
PGC-1 $\alpha$ 4 <sup>69</sup>	111.9	5'-TCACACCAAACCCACAGAGA-3'	5'-TCACACCAAACCCACAGAGA-3'
COX IV	103.6	5'-GAGCAATTTCCACCTCTGC-3'	5'-CAGGAGGCCTTCTCCTTCTC-3'
CPT1	111.0	5'-ACAGTCGGTGAGGCCTCTTA-3'	5'-CCACCAGTCGCTCACGTAAT-3'
NDUF	109.0	5'-TCAGATTGCTGTCAGACATGG-3'	5'-TGGTGTCCCTTCTATCTTCCA-3'
SDH	105.0	5'-AAATGTGGCCCCATGGTATTG-3'	5'-AGAGCCACAGATGCCTTCTCTG-3'
Cytochrome C	98.8	5'-GGGCCAAATCTCCATGGTCT-3'	5'-TCTCCCCAGATGATGCCTTT-3'
GLUT4	103.6	5'-CTTCATCATTGGCATGGGTTT-3'	5'-AGGACCGCAAATAGAAGGAAGA-3'
$\beta$ -HAD	80.6	5'-TGGACAAGTTTGTCTGAACAT-3'	5'-TTTCATGACAGGCACTGGGT-3'
CD-36	119.0	5'-TTGATTGAAAAATCCTTCTTAGCCA-3'	5'-TGGTTTCTACAAGCTCTGGTTCTT-3'
PFK	97.6	5'-AAGACATCAAGAATCTGGTGGTTA-3'	5'-TCCAAAAGTGCCATCACTGC-3'
CS	113.5	5'-TGGGGTGTCTCCAGTATT-3'	5'-CCAGTACACCAATGCTCGT-3'
PPAR $\alpha$	92.7	5'-GGCAGAAGAGCCGTCTCTACTTA-3'	5'-TTTGCATGGTTCTGGGTACTGA-3'
PPAR $\delta$	109.0	5'-CTTGTGAAGGATGCAAGGGTT-3'	5'-GAGACATCCCCACTGCAAGG-3'
UCP3	89.5	5'-CCACAGCCTTCTACAAGGGATTTA-3'	5'-ACGAACATCACCACGTTCCA-3'
Tfam	109.3	5'-CCGAGGTGGTTTTTCATCTGT-3'	5'-GCATCTGGGTTCTGAGCTTT-3'
PDK4	99.7	5'-GCAGCTACTGGACTTTGGTT-3'	5'-GCGAGTCTCACAGGCAATTC-3'
p53	101.8	5'-GTTCCGAGAGCTGAATGAGG-3'	5'-TTATGGCGGGAGGTAGACTG-3'
PPAR $\beta/\delta$	103.7	5'-CATCATTCTGTGTGGAGACCG-3'	5'-AGAGGTACTGGGCATCAGGG-3'
TEFB	102.0	5'-CAGATGCCCAACACGCTACC-3'	5'-GCATCTGTGAGCTCTCGCTT-3'
CHCHD4	107.0	5'-GCTTGGCTGTTTCTTGTATTTC-3'	5'-GTTTCTCTCTTGTCTGCTACTC-3'
p21	99.8	5'-GCAGACCAGCATGACAGATTT-3'	5'-GATGTAGAGCGGGCCTTTGA-3'
GAPDH	106.0	5'-AATCCCATCACCATCTTCCA-3'	5'-TGGACTCCACGACGACTACTCA-3'
B2M	98.0	5'-TGCTGTCTCCATGTTTGATGTATCT-3'	5'-TCTCTGCTCCCCACCTCTAAGT-3'
TBP	99.0	5'-CAGTGACCCAGCAGCATCACT-3'	5'-AGGCCAAGCCCTGAGCGTAA-3'
Cyclophilin	100.0	5'-GTCAACCCACCGTGTCTTTC-3'	5'-TTTCTGCTGTCTTTGGACCTTG-3'
18S	99.0	5'-CTTAGAGGGACAAGTGGCG-3'	5'-GGACATCTAAGGGCATCACA-3'
ACTB	107.0	5'-GAGCACAGAGCCTCGCCTTT-3'	5'-TCATCATCCATGGTGAGCTGGC-3'

PGC- 1 $\alpha$ , peroxisome proliferator-activated receptor- $\alpha$  coactivator 1 $\alpha$ ; COX IV, cytochrome c oxidase subunit IV; CPT1, carnitine palmitoyltransferase 1; NDUF, NADH:ubiquinone oxidoreductase; SDH, succinate dehydrogenase; GLUT4, Glucose transporter type 4;  $\beta$ -HAD, 3-hydroxyacyl-CoA dehydrogenase; CD36, fatty acid translocase cluster of differentiation 36; PFK, phosphofructokinase; CS, citrate synthase; PPAR $\alpha$ , peroxisome proliferator-activated receptor alpha; PPAR $\delta$ , peroxisome proliferator-activated receptor delta; UCP3, uncoupling protein 3; Tfam, mitochondrial transcription factor A; PDK4, pyruvate dehydrogenase kinase 4; p53, p53 protein; PPAR $\beta/\delta$ , peroxisome proliferator-activated receptor beta/delta; TEFB, transcription elongation factor; CHCHD4, coiled-coil-helix-coiled-coil-helix domain containing 4; p21, p21 protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; B2M,  $\beta$ -2-microglobulin; TBP, TATA-box binding protein; 18S, 18S ribosomal RNA; ACTB, actin beta.